Impax Asset Management Group plc now owns 1,466,461 shares of the medical research company’s stock worth $294,847,000 after buying an additional 349,547 shares during the last quarter. Finally, Impax Asset Management Group plc increased its holdings in PerkinElmer by 31.3% in the fourth quarter. State Street Corp now owns 5,065,241 shares of the medical research company’s stock valued at $1,018,417,000 after buying an additional 583,525 shares in the last quarter.
![perkins elmer perkins elmer](https://lmg-labmanager.s3.amazonaws.com/assets/articleNo/22538/iImg/41799/apr29-2020-perkinelmer-s23-autosampler.png)
State Street Corp grew its stake in shares of PerkinElmer by 13.0% in the 4th quarter. now owns 8,394,690 shares of the medical research company’s stock valued at $1,687,835,000 after buying an additional 953,169 shares during the last quarter. lifted its holdings in shares of PerkinElmer by 12.8% during the 4th quarter. Norges Bank purchased a new stake in shares of PerkinElmer during the 4th quarter worth about $247,666,000. Capital Research Global Investors now owns 14,317,805 shares of the medical research company’s stock valued at $2,497,944,000 after purchasing an additional 1,235,625 shares during the last quarter. Capital Research Global Investors boosted its position in PerkinElmer by 9.4% during the first quarter. Institutional investors and hedge funds have recently modified their holdings of the stock. Corporate insiders own 0.52% of the company’s stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Following the transaction, the insider now directly owns 27,577 shares of the company’s stock, valued at $4,012,177.73. The stock was sold at an average price of $145.49, for a total transaction of $731,087.25. Mock sold 5,025 shares of the company’s stock in a transaction on Friday, June 24th. This represents a $0.28 annualized dividend and a yield of 0.19%. Shareholders of record on Friday, October 21st will be given a dividend of $0.07 per share. The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 11th. As a group, sell-side analysts expect that PerkinElmer will post 7.3 earnings per share for the current year. During the same quarter in the prior year, the business earned $3.72 earnings per share. PerkinElmer’s quarterly revenue was down 3.7% on a year-over-year basis. PerkinElmer had a net margin of 14.54% and a return on equity of 18.98%. The firm had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.19 billion. The medical research company reported $2.41 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.33. PerkinElmer ( NYSE:PKI – Get Rating) last released its quarterly earnings data on Tuesday, May 3rd. According to MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $156.73.
![perkins elmer perkins elmer](https://images-na.ssl-images-amazon.com/images/I/31sTtGTwamL._SX342_.jpg)
One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. They issued a hold rating for the company. Finally, initiated coverage on PerkinElmer in a research report on Thursday, March 31st. They issued an underweight rating and a $125.00 price objective for the company. Barclays assumed coverage on shares of PerkinElmer in a report on Tuesday, May 17th. Baird decreased their target price on shares of PerkinElmer from $216.00 to $198.00 in a research report on Wednesday, May 4th. Citigroup decreased their target price on shares of PerkinElmer from $185.00 to $170.00 in a research report on Wednesday, May 4th. The Goldman Sachs Group dropped their price objective on shares of PerkinElmer from $200.00 to $175.00 and set a neutral rating on the stock in a research note on Thursday, July 14th. PKI has been the topic of several other research reports. The firm issued a buy rating and a $160.00 price objective on the medical research company’s stock. UBS Group initiated coverage on shares of PerkinElmer ( NYSE:PKI – Get Rating) in a research note issued to investors on Wednesday morning, The Fly reports.